

COSIRA II Media Toolkit

Guide Summary

The following guide contains key messages, images and logos for the COSIRA II clinical trial, a multicenter, randomized, double-blinded, sham-controlled clinical trial that is currently enrolling people with recurring, chronic (refractory) angina in sites across the U.S.A.

This information can be used to develop external materials like press releases, social media posts, or newsletters to educate your physician and patient communities, as well as your internal hospital associates with materials like employee newsletters or emails.

Johnson & Johnson MedTech and Shockwave Medical are not to create materials for any desired outreach.

Disclaimer

Because the Shockwave Balloon-expandable Coronary Sinus Reducer is currently an investigational device in the U.S., it is recommended to use the following disclaimer for any assets you create: “Caution: In the United States, Shockwave Reducer is an investigational device, limited by United States law to investigational use.”

COSIRA II Clinical Trial Key Messages

This information should not be edited.

- COSIRA II (COSIRA = COronary Sinus Reducer for treatment of Refractory Angina II) is a multicenter, randomized, double-blinded, sham-controlled clinical trial that is currently enrolling people with recurring, chronic (refractory) angina in sites across the U.S.ⁱⁱ
- The COSIRA II trial is designed to evaluate the safety and effectiveness of Shockwave™ Balloon-expandable Coronary Sinus Reducer, a new investigational device in the U.S. for the treatment of refractory angina in adults with recurring, chronic angina when additional medical therapy and procedures are not an option.
- The Shockwave Balloon-expandable Coronary Sinus Reducer, an investigational device in the United States currently being studied in the COSIRA II trial, is an innovative technology designed to treat symptoms of recurring, chronic angina by creating a permanent, controlled narrowing of the coronary sinus. The resulting increase in back pressure reduces angina symptoms by a hypothesized redistribution of blood into the ischemic myocardium.ⁱⁱⁱ
- Shockwave™ Balloon-expandable Coronary Sinus Reducer is an investigational device in the United States. It is commercially available in some markets outside the U.S.^{iv}
- Physicians who want to learn more about the COSIRA II clinical trial, including participating sites and eligibility criteria, can visit <https://shockwavemedical.com/clinical-evidence/cosira-ii/> for more information.
- Individuals living with chronic angina—or their family members—who would like to learn more about the COSIRA II clinical trial, including participating sites and eligibility criteria, can visit: <https://shockwavemedical.com/clinical-evidence/cosira-ii/>

About Chronic or Refractory Angina

- Angina, affects approximately 100 million people worldwide,^v including 11 million Americans.^{vi}
- Angina pain is often a symptom of coronary artery disease (CAD), which affects approximately 315 million people worldwide.^{vii}
- People with angina have more hospital visits, and having angina can double healthcare costs.^{viii}
- Many patients can get relief from their angina through revascularization from a coronary intervention or surgery. However, 20–40% continue to suffer from angina even after successful revascularization.^{ix}
- Usually, symptoms of myocardial ischemia (a lack of blood flow to the heart muscle) angina may feel like pressure or squeezing in the chest and/or pain in the shoulders, arms, neck, jaw or back. Many patients experience angina symptoms that are severe, long-lasting and uncontrollable by traditional medical therapies. This severely debilitating condition is known as recurring, chronic angina or refractory angina.
- Angina pain is often a symptom of coronary artery disease (CAD), when plaque buildup occurs in the arteries supplying the oxygen-rich blood to the heart, reducing blood flow to the heart muscle.
- Angina with nonobstructive coronary arteries (ANOCA) is increasingly recognized and may affect nearly half of all patients with angina.^x

Graphics and Images

Click the link. Once the image opens, right click to save.

Currently, links to the black logo or patient and enlarged device photos are not available, and must be saved directly from this PDF.



Chest Pain



Chest Pressure



**Squeezing
Sensation in Chest**



Indigestion



**Pain That Spreads to
Your Neck, Jaw, Arms,
Back, or Belly**

Common symptoms of angina

[Link to image](#)




Shockwave™ Coronary Sinus Reducer

[Link to image](#)

5403 Betsy Ross Drive, Santa Clara, CA 95054 | 1-877-775-4846 | ShockwaveMedical.com

COSIRA II



Shockwave™ Coronary Sinus Reducer



Patient Image Kunigunde

5403 Betsy Ross Drive, Santa Clara, CA 95054 | 1-877-775-4846 | ShockwaveMedical.com

COSIRA II



Patient Image Shannon

COSIRA II

COSIRA II

COSIRA II Logos
[Link to orange logo](#)

5403 Betsy Ross Drive, Santa Clara, CA 95054 | 1-877-775-4846 | ShockwaveMedical.com

COSIRA II

Press Release Outline

HEADLINE

A concise, compelling statement announcing the key news or milestone

SUBHEAD

A supporting line that provides additional context or impact to the headline

DATELINE + LEAD PARAGRAPH

City, State — Month Day, Year —

A strong opening paragraph summarizing:

- What is being announced
- Why it matters to clinicians, patients or the community
- High-level benefit or impact level benefit or impact-level benefit or impact

BACKGROUND PARAGRAPH(S)

Short optional paragraphs expanding on:

- The broader challenge or clinical need
- Context for how this news fits into improving patient care, workflow, or outcomes

SUPPORTING DETAILS / KEY HIGHLIGHTS

Bullet points or brief supporting paragraphs that may include:

- Key facts or data points about the product and how it will impact patient care
- Quotes from physicians, hospital leaders, or program managers

QUOTE

A statement from a senior leader emphasizing:

- Organizational commitment to innovation, quality, safety or patient outcomes
- How the announcement aligns with hospital mission or strategic goals

ABOUT THE HOSPITAL

A brief, general “About” section with non-product-specific language appropriate to the institution.

Example CALL TO ACTION

- Where to find more information
- Contacts for media inquiries

Citations

ⁱ Shockwave Medical. (2025). COSIRA II clinical trial. <https://shockwavemedical.com/clinical-evidence/cosira-ii/>

ⁱⁱ Shockwave Medical. (2025). COSIRA II clinical trial. <https://shockwavemedical.com/clinical-evidence/cosira-ii/>

ⁱⁱⁱ Verheye, Stefan, et al. JACC: Cardiovascular Interventions, vol. 17, no. 24, 2024, pp. 2908-2918.

^{iv} Shockwave Medical. (2025). *Shockwave Reducer*. <https://shockwavemedical.com/en-eu/products/shockwave-reducer/>

^v Povsic TJ et al. Circ: Cardiovascular Interventions. 2021 Feb;14(2):e009002.

^{vi} Agho AV, Disu F, Figueroa AS, Wiredu B, Okorigba EM, Olanite M, Okobi OE, Noman T. Prevalence of Angina Pectoris: An Analysis of the National Health Interview Survey (NHIS) Database. Cureus. 2025 Apr 27;17(4):e83076.

COSIRA II

^{vii} Stark, B, Johnson, C, Roth, G. (2024). "Global Prevalence of Coronary Artery Disease: An Update from the Global Burden of Disease Study." *JACC*, 83, pp. 2320.

^{viii} Kempf, J., et al. Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting. *American Health & Drug Benefits*, vol. 4, no. 6, 2011.

^{ix} Crea F, et al. *European Heart Journal*. 2019 Aug 1;40(29):2455-62.

^x Perera D, Berry C, Hoole SP, et al. *Heart* 2023;109:88–95.

SPL 80119, Rev. A